Recent Advances in Immune Checkpoint Inhibition and Antibody Drug Conjugates in Urothelial Carcinoma
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Genitourinary Oncology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 274
Special Issue Editor
Interests: kidney cancer; prostate cancer; bladder cancer; testicular cancer; VHL syndrome; clinical trials; biomarkers; novel therapeutics/therapeutic combinations
Special Issue Information
Dear Colleagues,
This Special Issue highlights recent advances in immune checkpoint inhibition and antibody drug conjugates for the treatment of urothelial carcinoma, focusing on the latest research and clinical developments in this area. It explores the role of immune checkpoint inhibitors and antibody drug conjugates in improving outcomes for patients with urothelial cancer, a disease historically characterized by poor prognosis in advanced stages. This Special Issue covers novel therapeutic combinations of immune checkpoint inhibitors and antibody drug conjugates as well as their combinations with chemotherapy, targeted therapies, and other immunotherapies aimed at enhancing treatment efficacy. It also addresses biomarkers for patient selection, resistance mechanisms, and strategies to overcome immune evasion. Furthermore, this Special Issue discusses the impact of immune checkpoint inhibition and antibody drug conjugates on overall survival, progression-free survival, and quality of life, with a focus on optimizing treatment regimens. By examining both the challenges and successes of these therapies in urothelial carcinoma, this Special Issue provides a comprehensive overview of the current landscape and future directions in this rapidly evolving field of bladder cancer treatment.
Dr. Qian Janie Qin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune checkpoint inhibition
- antibody drug conjugates
- urothelial carcinoma
- therapeutic combinations
- biomarkers
- resistance mechanisms
- treatment efficacy
- cancer immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
